LBLuish Borboruah

Luish Borboruah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luish Borboruah has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Unveiling Bone Health in Sickle Cell Disease: A Comprehensive Analysis of Bone Mineral Density

    by Sudem Narzari, Anupam Dutta, Ajit Kumar Pegu, Paramananda Taye, Luish Borboruah, Dipjyoti Boruah

    Sickle Cell Disease is a well-known haemoglobinopathy affecting a substantial load of population across the globe. Although mainly characterized by anaemia, the overall effects of the disease are not just limited to the haematological system and in fact involves the bones, renal and endocrine organs. The repeated Vaso-occlusive episodes in SCD imparts a negative impact on bone mineral density of the patients and affects the bone growth and metabolism. The study aims to evaluate the bone mineral density in patients with sickle cell disease and as well as establishing potential correlations between bone mineral density and the clinical manifestations of the disease. The present study was conducted in the Dept of Medicine, Assam Medical College & Hospital on 70 sickle cell disease patients. Detailed clinical history was taken and other relevant physical examinations and investigations like anthropometric measurements, routine haematological investigations and bone densitometry using Dual Energy X-ray Absorptiometry (DEXA) were done. Data were represented in appropriate format and statistical analysis was performed using SPSS and Microsoft Excel. Statistical significance was analysed by independent t test and chi square test. Out of the total of 70 participants of the study there were 26 male and 44 female participants. The mean age of patients was 24.72 years and majority of patients belonged to the tea tribe community. Based on DEXA scan, 45 patients (64.3%) were having low BMD defined as either osteopenia or osteoporosis. The prevalence of low BMD in the present study was higher at lumbar spine compared to neck of femur. Low BMD was significantly correlated with low BMI (pp=0.003), low calcium (p=0.001) and low ferritin level (p=0.001). There is an intricate interplay between low BMD in Sickle Cell Disease and various clinical parameters, revealing strong associations with low Body Mass Index, diminished haemoglobin levels, reduced calcium levels, and elevated serum ferritin levels. This emphasizes the need for comprehensive management strategies addressing nutritional, haematological, and metabolic factors to optimize bone health in this patient population.


  • Open Access

    Diagnostic performance of point-of-care ultrasonography (POC-US) in haemophilia joint health: a comparative study with MRI

    by Yash Duseja, Arnav Kashyap, Anupam Dutta, Dhrubajyoti Borpatragohain, Bhabani Dhal, Luish Borboruah

    Introduction: Haemophilia presents challenges in joint pathology assessment, prompting exploration of point-of-care ultrasonography (POC-US) as a diagnostic tool. Aims: The study aimed to assess the diagnostic performance of point-of-care ultrasonography (POC-US) compared to magnetic resonance imaging (MRI) in detecting synovial hypertrophy, cartilage abnormality, and bony abnormality among people with haemophilia (PWH) treated at Assam Medical College Hospital. Methods: Forty-two PWH underwent POC-US and MRI for joint assessment. The POC-US and MRI imaging interpretation involved calculating diagnostic accuracy parameters for POC-US and MRI scores. This included sensitivity, specificity, positive predictive value, and negative predictive value. Results: POC-US demonstrated a sensitivity of around 97% and specificity of 92% for detecting synovial hypertrophy, while showing a sensitivity of 85% and specificity of 100% for bony abnormality. Cartilage abnormality assessment revealed a sensitivity of 55% and specificity of 100%. Knee joint involvement was observed in all patients, with 7% also exhibiting ankle joint pathology. Disease severity distribution showed 57% with severe hemophilia, 24% with moderate, and 19% with mild disease. Conclusion: Our study highlights the diagnostic potential of POC-US in haemophilia management, particularly in detecting synovial hypertrophy and bony abnormality. Challenges in assessing cartilage abnormality warrant further investigation. These findings contribute to the discourse on POC-US in haemophilia management, emphasising the need for continued research to elucidate its clinical relevance.


  • Open Access

    Management of a patient with factor X deficiency with FEIBA: a case report

    by Luish Borboruah, Anupam Dutta

    Hereditary factor X (FX) deficiency is a rare autosomal recessive disorder that increases bleeding tendencies, ranging from epistaxis to intracranial haemorrhage (ICH), which can be life-threatening. Single factor concentrates are recommended for treating rare bleeding disorders; however, in India most people with FX deficiency are treated with fresh frozen plasma (FFP). We report a case of FX deficiency in a child with a history of intracranial bleeding who was found to have a novel mutation in the F10 gene. Although managed with weekly prophylactic FFP infusions, he continued to experience regular bleeding including two further instances of ICH. Other therapeutic options were unavailable or unaffordable. When the Indian Government added FEIBA to the essential drug list, a decision was made to try FEIBA prophylaxis to better manage his bleeding. In 2019, he was started on a weekly dose of FEIBA, 500 IU (20 IU/ kg and his prophylactic FFP transfusion regimen was stopped. His bleeding episodes started to reduce after two months of starting FEIBA prophylaxis. Over the last three years he has had only four minor bleeding episodes and has remained completely free of major bleeding. He is now able to receive home-based therapy and his prognosis can be considered to be improved. FEIBA may be a useful medicinal therapy for FX-deficient patients who suffer severe haemorrhagic episodes in countries where plasma-derived factor X (pdFX) is not available.